Latest News Releases From The Newsroom
Q1 Earnings Roundup: Akamai Beats Estimates, Axon Sees Slight Dip, Cutera Takes a Hit, and Wynn Resorts Holds Steady
May 09th, 2023
In the latest round of Q1 earnings reports, Akamai Technologies, Inc. (Nasdaq: AKAM) beat consensus estimates with an adjusted EPS of $1.40, compared to the expected $1.32. This news was well-received by investors, as AKAM's stock price increased by . Read more
Q1 Earnings Report Roundup: Ziff Davis Shines, Hyliion and Eos Energy Make Gains, B2Gold Sees Modest Increase
May 09th, 2023
Four companies have released their Q1 earnings reports, with three of them seeing positive movement in their after-hours trading prices. Hyliion Holdings Corp. (NYSE: HYLN) reported a Q1 loss of $0.16 per share, which was slightly better than the . Read more
Harmonic Beats Q1 Earnings Estimates, Trex Company Upgraded to Buy, MSCI Receives Overweight Rating and Price Target at Wells Fargo
May 09th, 2023
Harmonic Inc. (Nasdaq: HLIT) reported better than expected Q1 earnings, with adjusted earnings per share (EPS) of $0.12, beating the consensus estimate of $0.08. This news led to a surge in the company's stock price, which rose by 19.70% to $16.14 in. Read more
Longeveron's Lomecel-B shows promise for HLHS patients; Plug Power and Genius Sports report mixed Q1 earnings
May 09th, 2023
Longeveron Inc. (Nasdaq: LGVN) released new long-term follow-up data from its ELPIS I trial, highlighting the potential survival benefit of Lomecel-B for patients with hypoplastic left heart syndrome (HLHS). HLHS is a rare and life-threatening congen. Read more
Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
May 09th, 2023
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69. Meanwhile, Voyager Therapeutics. Read more
Novavax Reports Better-than-Expected Q1 Loss, Implements Cost-Cutting Measures to Extend Cash Runway and Improve Efficiency
May 09th, 2023
Novavax, Inc. (Nasdaq: NVAX) reported a Q1 loss of $3.41 per share, slightly better than the consensus loss of $3.46 per share. In response to the challenging times, the company has announced cost-cutting measures to extend its cash runway a. Read more
Ensysce Biosciences Announces Successful Completion of Clinical Study for Pain Medication with Overdose Protection, Amgen and TScan Therapeutics Collaborate to Identify Antigens for Crohn's Disease Treatment
May 09th, 2023
Ensysce Biosciences, Inc. (Nasdaq: ENSC) has completed the clinical study of its first pain medication with overdose protection, PF614-MPAR, known as PF614-MPAR-101. The final Part B of the study showed that PF614-MPAR effectively reduced opioid deli. Read more
ClearOne Declares Special Dividend, Shares Surge in Pre-market Trading
May 09th, 2023
ClearOne (NASDAQ: CLRO) has announced a special one-time cash dividend of $1.00 per share of ClearOne common stock, payable on May 31, 2023, to shareholders of record on May 22, 2023. Eric L. Robinson, the Chairman of the Board of Directors . Read more
Barclays Raises McKesson Price Target, Vertex Energy Misses Q1 Estimates, Atkore Beats Q2 Expectations
May 09th, 2023
McKesson Corporation (NYSE: MCK) has had its price target raised by Barclays from $415 to $420. The stock is responding positively in pre-market trading, currently up 4.44% to $384.94. However, Vertex Energy, Inc. (Nasdaq: VTNR) has reported Q1 ea. Read more
Market Update: AudioCodes Falls Short on Q1 Earnings, Howmet Aerospace Receives Price Target Boost, NeoGenomics Upgraded to Buy
May 09th, 2023
AudioCodes Ltd. (Nasdaq: AUDC) has reported Q1 earnings per share of $0.08, falling short of the consensus estimate of $0.17. Despite this, the stock is trading higher in pre-market, currently up 6.21% to $10.61. Barclays has raised the price targ. Read more
Member Login